Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.42 million versus the consensus estimate of $11.96 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Boxabl completes SPAC merger, begins trading on Nasdaq at $3.5B value
• Penguin Solutions closes $750M convertible notes offering due 2031